APGE Live signals | Maximize Profits with Getagraph.com

BUY 121242 min ago

@ $35.28

Issued: 14 Feb 2024 @ 15:02

Return: 45.29%

Previous signal: Feb 13 - 12:37

Previous signal: Sell

Return: 0.28 %

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 16:00):

Stats
Today's Volume	177 157
Average Volume	705 996
Market Cap	2.89B
EPS	$0 ( 2024-03-11 )
Next earnings date	( $-0.600 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0900 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Fairmount Funds Management Llc	Buy	51 166	Common Stock
2024-01-29	Fairmount Funds Management Llc	Sell	892 529	Common Stock
2023-12-18	Henderson Michael Thomas	Buy	398 512	Stock Option (Right to Buy)
2023-07-13	Fairmount Funds Management Llc	Buy	1 992 734	Common Stock
2023-07-13	Fairmount Funds Management Llc	Buy	892 529	Common Stock

INSIDER POWER
47.25
Last 9 transactions
Buy: 3 438 612 \| Sell: 892 529

Volume Correlation

Long: 0.26 (neutral)

Short: 0.83 (strong)

Signal:(78.086) Same movement expected

Apogee Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Apogee Therapeutics, Inc. Correlation - Currency/Commodity

0.05
( neutral )

-0.24
( neutral )

-0.41
( neutral )

-0.20
( neutral )

-0.63
( weak negative )

-0.45
( neutral )

Apogee Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.660

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.660

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.790

Financial Reports:

No articles found.

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.